Sistema de Gestión del Conocimiento ANLIS MALBRÁN
Not a member yet
3661 research outputs found
Sort by
First Clinical Isolation of an Azole-Resistant Aspergillus fumigatus Isolate Harboring a TR46 Y121F T289A Mutation in South America
No full textFil: Isla, Guillermina. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Micología; Argentina.Fil: Leonardelli, Florencia. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Cátedra de Parasitología y Micología. Laboratorio de Micología y Diagnóstico Molecular; Argentina.Fil: Tiraboschi, Iris N. Hospital de Clínicas José de San Martín; Argentina.Fil: Refojo, Nicolás. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Micología; Argentina.Fil: Hevia, Alejandra. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Micología; Argentina.Fil: Vivot, Walter. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Micología; Argentina.Fil: Szusz, Wanda. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Micología; Argentina.Fil: Córdoba, Susana B. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Micología; Argentina.Fil: García-Effron, Guillermo. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Cátedra de Parasitología y Micología. Laboratorio de Micología y Diagnóstico Molecular; Argentina.One of the most recently described Aspergillus fumigatusCYP51A-mediated azole resistance mechanisms is TR46 Y121F T289A. Clinical A. fumigatus strains harboring these substitutions have been reported worldwide, with the exception of South America. We describe the first clinical A. fumigatus strain with this resistance mechanism isolated from an Argentinian patient. The strain was isolated in 2009 (1 year after the first-described mutant in United States), demonstrating that these alleles were scattered worldwide earlier than previously thought
Unusual genetic variants associated with hypercholesterolemia in Argentina
No full textFil: Corral, Pablo. Departamento de Investigación, Facultad de Medicina, Universidad FASTA, Buenos Aires; Argentina.Fil: Geller, Andrew S. Boston Heart Diagnostics, Framingham, MA; Estados Unidos.Fil: Polisecki, Eliana Y. Boston Heart Diagnostics, Framingham, MA; Estados Unidos.Fil: Lopez, Graciela I. Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Laboratorio de Lípidos y Aterosclerosis, INFIBIOC-UBA, Buenos Aires; Argentina.Fil: Bañares, Virginia. ANLIS Dr.C.G.Malbrán. Centro Nacional de Genética Médica; Argentina.Fil: Cacciagiu, Leonardo. Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Laboratorio de Lípidos y Aterosclerosis, INFIBIOC-UBA, Buenos Aires; Argentina.Fil: Berg, Gabriela. Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Laboratorio de Lípidos y Aterosclerosis, INFIBIOC-UBA, Buenos Aires; Argentina.Fil: Hegele, Robert A. Robarts Research Institute, University Western Ontario, London, Ontario; Canada.Fil: Schaefer, Ernst J. Boston Heart Diagnostics, Framingham, MA; Estados Unidos.Fil: Schreier, Laura. Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Laboratorio de Lípidos y Aterosclerosis, INFIBIOC-UBA, Buenos Aires; Argentina.Marked hypercholesterolemia, defined as low density lipoprotein cholesterol (LDL-C) levels ≥ 190 mg/dL, may be due to LDLR, APOB, and PCSK9 variants. In a recent analysis, only 1.7% of cases had such variants. Our goal was to identify other potential genetic causes of hypercholesterolemia
Genetic Imbalances in Argentinean Patients with Congenital Conotruncal Heart Defects
Get PDFFil: Delea, Marisol. ANLIS Dr.C.G.Malbrán. Centro Nacional de Genética Médica; Argentina.Fil: Espeche, Lucía D. ANLIS Dr.C.G.Malbrán. Centro Nacional de Genética Médica; Argentina.Fil: Bruque, Carlos D. ANLIS Dr.C.G.Malbrán. Centro Nacional de Genética Médica; Argentina.Fil: Bidondo, María Paz. ANLIS Dr.C.G.Malbrán. Centro Nacional de Genética Médica; Argentina.Fil: Massara, Lucía S. Hospital El Cruce Dr. Néstor Kirchner; Argentina.Fil: Oliveri, Jaen. Hospital El Cruce Dr. Néstor Kirchner; Argentina.Fil: Brun, Paloma. Hospital El Cruce Dr. Néstor Kirchner; Argentina.Fil: Cosentino, Viviana R. Hospital Gandulfo. Departamento de Neonatología; Argentina.Fil: Martinoli, Celeste. Hospital Sor María Ludovica. Servicio de Genética; Argentina.Fil: Tolaba, Norma. Hospital Dr. Arturo Oñativia; Argentina.Fil: Picon, Claudina. Hospital Pediátrico Dr. Avelino Castelán; Argentina.Fil: Ponce Zaldua, María Eugenia. Hospital Provincial Neuquén Dr. Eduardo Castro Rendón. Servicio de Genética; Argentina.Fil: Ávila, Silvia. Hospital Provincial Neuquén Dr. Eduardo Castro Rendón. Servicio de Genética; Argentina.Fil: Gutnisky, Viviana. Laboratorio Central de Redes y Programas de Corrientes; Argentina.Fil: Pérez, Myriam. ANLIS Dr.C.G.Malbrán. Centro Nacional de Genética Médica; Argentina.Fil: Furforo, Lilian. Hospital Materno Infantil Dr. Ramón Sardá; Argentina.Fil: Buzzalino, Noemí D. ANLIS Dr.C.G.Malbrán. Centro Nacional de Genética Médica; Argentina.Fil: Liascovich, Rosa. ANLIS Dr.C.G.Malbrán. Centro Nacional de Genética Médica; Argentina.Fil: Groisman, Boris. ANLIS Dr.C.G.Malbrán. Centro Nacional de Genética Médica; Argentina.Fil: Rittler, Mónica. Hospital Materno Infantil Dr. Ramón Sardá; Argentina.Fil: Rozental, Sandra. ANLIS Dr.C.G.Malbrán. Centro Nacional de Genética Médica; Argentina.Fil: Barbero, Pablo. ANLIS Dr.C.G.Malbrán. Centro Nacional de Genética Médica; Argentina.Fil: Dain, Liliana. ANLIS Dr.C.G.Malbrán. Centro Nacional de Genética Médica; Argentina.Congenital conotruncal heart defects (CCHD) are a subset of serious congenital heart defects (CHD) of the cardiac outflow tracts or great arteries. Its frequency is estimated in 1/1000 live births, accounting for approximately 10⁻30% of all CHD cases. Chromosomal abnormalities and copy number variants (CNVs) contribute to the disease risk in patients with syndromic and/or non-syndromic forms. Although largely studied in several populations, their frequencies are barely reported for Latin American countries. The aim of this study was to analyze chromosomal abnormalities, 22q11 deletions, and other genomic imbalances in a group of Argentinean patients with CCHD of unknown etiology. A cohort of 219 patients with isolated CCHD or associated with other major anomalies were referred from different provinces of Argentina. Cytogenetic studies, Multiplex-Ligation-Probe-Amplification (MLPA) and fluorescent in situ hybridization (FISH) analysis were performed. No cytogenetic abnormalities were found. 22q11 deletion was found in 23.5% of the patients from our cohort, 66% only had CHD with no other major anomalies. None of the patients with transposition of the great vessels (TGV) carried the 22q11 deletion. Other 4 clinically relevant CNVs were also observed: a distal low copy repeat (LCR)D-E 22q11 duplication, and 17p13.3, 4q35 and TBX1 deletions. In summary, 25.8% of CCHD patients presented imbalances associated with the disease
Sepsis secondary to complicated skin and soft tissue infection caused by Ignatzschineria indica. First case report in Latin America
No full textFil: Cipolla, Lucía. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Bacteriología. Servicio de Bacteriología Especial; Argentina.Fil: Derdoy, Laura. Sección Microbiología, Hospital 'Dr. J. M. Ramos Mejía', Buenos Aires; Argentina.Fil: Archuby, Daniela. Sección Microbiología, Hospital 'Dr. J. M. Ramos Mejía', Buenos Aires; Argentina.Fil: Tarzia, Adriana. Sección Microbiología, Hospital 'Dr. J. M. Ramos Mejía', Buenos Aires; Argentina.Fil: Govedic, Francisco. Servicio de Infectología, Sanatorio Allende, Córdoba; Argentina.Fil: Prieto, Mónica A. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Bacteriología. Servicio de Bacteriología Especial; Argentina.Ignatzschineria is a recently recognized genus associated with larvae infestation Members of this genus are pathogens infrequently implicated in human disease. During the last decade, fewer than 10 cases of infection with Ignatzchineria species have been reported around the world. Bacteria of the genera Ignatzchineria and Wohlfahrtiimonas have been isolated from larvae of the parasitic fly Wohlfahrtia magnifica, which is found in Europe, Asia and North Africa, and is associated with myiasis in several animal species, but rarely in humans
Spatial difference in the incidence of Argentine Hemorrhagic Fever and composition and abundance of rodents in the assemblage
No full textFil: Piacenza, María F. Facultad de Ciencias Exactas, Físico-Químicas y Naturales, Universidad Nacional de Río Cuarto, Río Cuarto, Córdoba; Argentina.Fil: Calderón, Gladys E. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina.Fil: Enría, Delia. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina.Fil: Provensal, María C. Facultad de Ciencias Exactas, Físico-Químicas y Naturales, Universidad Nacional de Río Cuarto, Río Cuarto, Córdoba; Argentina.Fil: Polop, Jaime J. Facultad de Ciencias Exactas, Físico-Químicas y Naturales, Universidad Nacional de Río Cuarto, Río Cuarto, Córdoba; Argentina.The Argentine Hemorrhagic Fever (AHF) is a zoonotic disease endemic in a wide area of the humid pampa of Argentina. The etiologic agent is the Junin virus that is maintained in the wild by the rodent Calomys musculinus and transmitted to humans, mainly, through aerosols generated from secretions and excretions
Performance of a highly successful outbreak strain of Mycobacterium tuberculosis in a multifaceted approach to bacterial fitness assessment
Get PDFFil: Yokobori, Noemí. Consejo Nacional de Investigaciones Científicas y Técnicas de Argentina. Academia Nacional de Medicina. Instituto de Medicina Experimental (IMEX), Buenos Aires; Argentina.Fil: López, Beatriz. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Monteserin, Johana. Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires; Argentina.Fil: Paul, Roxana. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Von Groll, Andrea. Universidade Federal do Rio Grande. Faculty of Medicine. Medical Microbiology Research Center, Porto Alegre, Río Grande del Sur; Brasil.Fil: Martin, Anandi. Université Catholique de Louvain. Institute of Experimental and Clinical Research. Pôle of Medical Microbiology, Bruselas; Bélgica.Fil: Marquina-Castillo, Brenda. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Sección de Patología Experimental, Ciudad de México; México.Fil: Palomino, Juan Carlos. Ghent University. Laboratory of Microbiology, Gante; Bélgica.Fil: Hernández-Pando, Rogelio. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Sección de Patología Experimental, Ciudad de México; México.Fil: Sasiain, María Del Carmen. Consejo Nacional de Investigaciones Científicas y Técnicas de Argentina. Academia Nacional de Medicina. Instituto de Medicina Experimental (IMEX), Buenos Aires; Argentina.Fil: Ritacco, Viviana. Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires; Argentina.Determining bacterial fitness represents a major challenge and no single parameter can accurately predict the ability of a certain pathogen to succeed. The M strain of Mycobacterium tuberculosis managed to spread and establish in the community and caused the largest multidrug-resistant tuberculosis outbreak in Latin America. We have previously shown that the M strain can manipulate the host immune response, but we still have no direct evidence, other than epidemiology, that can account for the enhanced fitness of the M strain. Our objective was to further characterize the performance of the outbreak strain M in different fitness assays. Two main aspects were evaluated: (1) molecular characterization of selected isolates from the M outbreak and related strains and (2) comparative fitness and in vivo performance of representative M strain isolates vs. the non-prosperous M strain variant 410. Our approach confirmed the multifaceted nature of fitness. Altogether, we conclude that the epidemiologically abortive strain 410 was vulnerable to drug-driven pressure, a weak competitor, and a stronger inductor of protective response in vivo. Conversely, the isolate 6548, representative of the M outbreak peak, had a growth disadvantage but performed very well in competition and induced lung damage at advanced stages in spite of reaching relatively low CFU counts. Integration of these observations supports the idea that the M strain managed to find a unique path to success
Autoevaluación de programas de prevención y control de infecciones asociadas al cuidado de la salud
No full textFil: Díaz, Carolina. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Epidemiología. Programa Nacional de Vigilancia de Infecciones Hospitalarias (VIHDA); Argentina.Fil: Lerena Giordano, Roberto. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Epidemiología. Programa Nacional de Vigilancia de Infecciones Hospitalarias (VIHDA); Argentina.Fil: Peralta, Norma. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Epidemiología. Programa Nacional de Vigilancia de Infecciones Hospitalarias (VIHDA); Argentina.Fil: Tiseira, Patricia. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Epidemiología. Programa Nacional de Vigilancia de Infecciones Hospitalarias (VIHDA); Argentina.Las Infecciones Asociadas al Cuidado de la Salud continúan representando un grave problema sanitario debido a su impacto asistencial, económico y social. El consenso interinstitucional entre el Instituto Nacional de Epidemiología, la Sociedad Argentina de Infectología y la Asociación de Enfermeros en Control de Infecciones, definió un sistema de autoevaluación de los Programas de Prevención y Control de Infecciones Asociadas al Cuidado de la Salud para instituciones de Argentina. El Programa Nacional de Vigilancia de Infecciones Hospitalarias de Argentina llevó adelante la primera edición de la Autoevaluación de los Programas Hospitalarios de Prevención y Control de Infecciones Asociadas al Cuidado de la Salud. El estudio fue soportado por una plataforma tecnológica desarrollada ad hoc en el marco del Proyecto de Desarrollo Tecnológico Social “Sistema Nacional de Evaluación de Programas de Prevención y Control de Infecciones Asociadas al Cuidado de la Salud” del Grupo Interinstitucional de Investigación y Desarrollo entre la Universidad FASTA y el Instituto Nacional de Epidemiología. El artículo presenta las características del estudio realizado en 13 instituciones de salud, cuyos resultados contribuyen al análisis de la situación y a una adecuada planificación de la intervención a fin de que los hospitales alcancen los mejores indicadores posibles mediante procesos razonables, factibles y efectivos
Distinct Treatment Outcomes of Antiparasitic Therapy in Trypanosoma cruzi-Infected Children Is Associated With Early Changes in Cytokines, Chemokines, and T-Cell Phenotypes
Get PDFBackground: In contrast to adults, Trypanosoma cruzi-infected children have more broadly functional Trypanosoma cruzi-specific T cells, and the total T-cell compartment exhibits fewer signs of immune exhaustion. However, not much is known about the link between immunocompetence and the treatment efficacy for human Chagas disease. Methods: Using cytokine enzyme-linked immunosorbent spot (ELISPOT) polychromatic flow cytometry, cytometric bead assay, multiplex serological assays and quantitative PCR, we evaluated T. cruzi-specific T-cell and antibody immune responses, T-cell phenotypes and parasitemia in children in the early chronic phase of Chagas disease undergoing anti-Trypanosoma cruzi treatment. Results: Treatment with benznidazole or nifurtimox induced a decline in T. cruzi-specific IFN-γ- and IL-2-producing cells and proinflammatory cytokines and chemokines. T-cell responses became detectable after therapy in children bearing T-cell responses under background levels prior to treatment. The total frequencies of effector, activated and antigen-experienced T cells also decreased following anti-T. cruzi therapy, along with an increase in T cells expressing the receptor of the homeostatic cytokine IL-7. Posttreatment changes in several of these markers distinguished children with a declining serologic response suggestive of successful treatment from those with sustained serological responses in a 5-year follow-up study. A multivariate analysis demonstrated that lower frequency of CD4+CD45RA-CCR7-CD62L- T cells prior to drug therapy was an independent indicator of successful treatment. Conclusions: These findings further validate the usefulness of alternative metrics to monitor treatment outcomes. Distinct qualitative and quantitative characteristics of T cells prior to drug therapy may be linked to treatment efficacy
Anti-inflammatory agents reduce microglial response, demyelinating process and neuronal toxin uptake in a model of encephalopathy produced by Shiga Toxin 2
No full textFil: Pinto, Alipio. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Fisiología y Biofísica "Houssay". Laboratorio de Neurofisiopatología; Argentina.Fil: Berdasco, Clara. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Fisiología y Biofísica "Houssay". Laboratorio de Neurofisiopatología; Argentina.Fil: Arenas-Mosquera, David. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Fisiología y Biofísica "Houssay". Laboratorio de Neurofisiopatología; Argentina.Fil: Cangelosi, Adriana. ANLIS Dr.C.G.Malbrán. Centro Nacional de Control de Calidad de Biológicos (CNCCB); Argentina.Fil: Geoghegan, Patricia A. ANLIS Dr.C.G.Malbrán. Centro Nacional de Control de Calidad de Biológicos (CNCCB); Argentina.Fil: Nuñez, Myriam C. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Matemáticas; Argentina.Fil: Goldstein, Jorge. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Fisiología y Biofísica "Houssay". Laboratorio de Neurofisiopatología; Argentina.Infections by Enterohemorrhagic Escherichia coli may cause in addition to hemolytic uremic syndrome neurological disorders which may lead to fatal outcomes in patients. The brain striatum is usually affected during this outcome. The aim of this study was to determine in this area the role of the microglia in pro-inflammatory events that may occur during Shiga toxin 2 intoxication and consequently to this, whether oligodendrocytes were being affected. In the present paper we demonstrated that anti-inflammatory treatments reduced deleterious effects in brain striatal cells exposed to Shiga toxin 2 and LPS. While dexamethasone treatment decreased microglial activation and recovered myelin integrity in the mice striatum, etanercept treatment decreased neuronal uptake of Stx2 in rat striatal neurons, improving the affected area from toxin-derived injury. In conclusion, microglial activation is related to pro-inflammatory events that may deteriorate the brain function during intoxication with Stx2 and LPS. Consequently, the role of anti-inflammatory agents in the treatment of EHEC-derived encephalopathy should be studied in clinical trials
Prevalence of Pertussis Antibodies in Maternal Blood, Cord Serum, and Infants From Mothers With and Those Without Tdap Booster Vaccination During Pregnancy in Argentina
Get PDFFil: Fallo, Aurelia A. Department of Pediatric Infectious Diseases, School of Medicine, Hospital de Niños "Ricardo Gutiérrez," University of Buenos Aires; Argentina.Fil: Neyro, Silvina E. Department of Pediatric Infectious Diseases, School of Medicine, Hospital de Niños "Ricardo Gutiérrez," University of Buenos Aires; Argentina.Fil: Manonelles, Gabriela V. Department of Pediatric Infectious Diseases, School of Medicine, Hospital de Niños "Ricardo Gutiérrez," University of Buenos Aires; Argentina.Fil: Lara, Claudia. Administración Nacional de Laboratorios e Institutos de Salud “Dr. Carlos G. Malbrán” (ANLIS); Argentina.Fil: Hozbor, Daniela. Laboratorio VacSal, Instituto de Biotecnología y Biología Molecular (IBBM), Facultad de Ciencias Exactas, Universidad Nacional de La Plata, CCT-CONICET; Argentina.Fil: Zintgraff, Jonathan. Administración Nacional de Laboratorios e Institutos de Salud “Dr. Carlos G. Malbrán” (ANLIS); Argentina.Fil: Mazzeo, Silvina. Departments of Obstetrics and Gynecology, Hospital D. F. Santojanni, Buenos Aires; Argentina.Fil: Davison, Héctor E. Departments of Obstetrics and Gynecology, Hospital D. F. Santojanni, Buenos Aires; Argentina.Fil: González, Susana. Pediatrics, Hospital D. F. Santojanni, Buenos Aires; Argentina.Fil: Zapulla, Estella. Pediatrics, Hospital D. F. Santojanni, Buenos Aires; ArgentinaFil: Canle, Oscar. Blood Center, Hospital de Niños "Ricardo Gutiérrez," Buenos Aires; ArgentinaFil: Huespe, Miguel. Departments of Obstetrics and Gynecology, Hospital D. F. Santojanni, Buenos Aires; Argentina.Fil: Galas, Marcelo. Administración Nacional de Laboratorios e Institutos de Salud “Dr. Carlos G. Malbrán” (ANLIS); Argentina.Fil: López, Eduardo L. Department of Pediatric Infectious Diseases, School of Medicine, Hospital de Niños "Ricardo Gutiérrez," University of Buenos Aires; Argentina.Morbidity and mortality rates for pertussis in infants are high because disease often occurs before the onset of routine immunization or in those who do not complete a primary immunization series. Pertussis immunization is recommended during pregnancy to achieve antibody levels sufficient to protect young infants. To our knowledge, no previous reports of maternal pertussis immunization results in Latin America exist in the literature